U.S. Biosimilars Market Size & Outlook, 2020-2027
U.S. biosimilars market, 2016-2027 (US$M)
Related Markets
U.S. biosimilars market highlights
- The U.S. biosimilars market generated a revenue of USD 2,500.0 million in 2020 and is expected to reach USD 13,490.0 million by 2027.
- The U.S. market is expected to grow at a CAGR of 27.2% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2020 | USD 2,500.0 million |
| Market revenue in 2027 | USD 13,490.0 million |
| Growth rate | 27.2% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 18.9% of the global biosimilars market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. biosimilars market is projected to lead the regional market in terms of revenue in 2027.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 13,490.0 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.86% in 2020. Horizon Databook has segmented the U.S. biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
While the U.S. biosimilars market is less mature than Europe’s, there has been a considerable rise in the number of biosimilars being approved by regulatory authorities, which can improve the impact of biosimilars in the U.S. market. As of 2019, FDA approved 18 biosimilars, with more expected to be approved and launched by 2020.
In addition, FDA created a program to provide product-specific and detailed advice to manufacturers that plan on submitting applications for approval of biosimilars. As of 2018, only 68 manufacturer programs were enrolled in the FDA’s biosimilar development program, which increased to 90 by 2019.
Thus, the U.S. biosimilars market is anticipated to witness exponential growth over the forecast period, owing to increase in government initiatives that further the development of biosimilars. Such initiatives are expected to increase the adoption of biosimilars, thereby reducing healthcare costs.
Reasons to subscribe to U.S. biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. biosimilars market size, by product, 2016-2027 (US$M)
U.S. Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
